Enzon Pharmaceuticals Files 2023 Annual Report on Form 10-K

TL;DR

<b>Enzon Pharmaceuticals filed its 2023 10-K, detailing financial positions and historical stock events.</b>

AI Summary

ENZON PHARMACEUTICALS, INC. (ENZN) filed a Annual Report (10-K) with the SEC on March 20, 2024. Enzon Pharmaceuticals, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing details financial data including retained earnings and additional paid-in capital for multiple fiscal years. Key dates related to Series C Preferred Stock issuances and rights offerings are noted. The company's business address is located at 20 Commerce Drive, Suite 135, Cranford, NJ 07016. Enzon Pharmaceuticals operates within the Biological Products sector.

Why It Matters

For investors and stakeholders tracking ENZON PHARMACEUTICALS, INC., this filing contains several important signals. This filing provides a comprehensive overview of Enzon's financial health and corporate actions for the fiscal year 2023, crucial for investors assessing the company's stability and performance. The inclusion of historical stock data, such as Series C Preferred Stock and rights offerings, offers insight into past financing strategies and potential future capital-raising activities.

Risk Assessment

Risk Level: low — ENZON PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant negative or positive news, indicating a status quo assessment.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Enzon Pharmaceuticals' current operational and financial standing.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported fiscal year end date)
• 2024-03-20 — Filing Date (Date the 10-K was filed)
• 2020-09-30 — Series C Preferred Stock Date (Date related to Series C Preferred Stock)
• 2020-10-09 — Investment Agreement Date (Date of Investment Agreement related to Series C Preferred Stock)

Key Players & Entities

• ENZON PHARMACEUTICALS, INC. (company) — Filer name
• ENZN (company) — Ticker symbol
• 20 COMMERCE DRIVE, SUITE 135 (company) — Business address
• CRANFORD (company) — Business address city
• NJ (company) — Business address state
• 07016 (company) — Business address zip
• 732-980-4500 (company) — Business phone
• Icahn Capital LP (company) — Related entity

FAQ

Industry Context

Enzon Pharmaceuticals operates in the Biological Products sector, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports on Form 10-K.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management discussion.
2. Analyze the historical stock-related events mentioned in the filing for insights into capital structure.
3. Assess any disclosed risk factors that may impact future operations.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-20: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual report for the fiscal year 2023, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.01 — ection 12(g) of the Act: Common Stock, $0.01 par value Series A-1 Junior Participa
• $0.20 — arket of the OTC Markets Group, Inc. of $0.20 per share reported for such date. Share
• $43.6 million — Financial Statements), and we realized $43.6 million in gross proceeds. This has enabled us
• $102.5 million — realize the value of our approximately $102.5 million NOLs by acquiring businesses or assets,
• $0 — icense maintenance fee of approximately $0 and $26,000, respectively, from Amgen,
• $26,000 — maintenance fee of approximately $0 and $26,000, respectively, from Amgen, Inc. in paym
• $43.1 million — erest income. We received approximately $43.1 million of net proceeds in the fourth quarter o
• $1,000 — ess of the initial liquidation value of $1,000 per share of Series C Preferred Stock o
• $0.10 — our stock's bid price had closed below $0.10 for more than 30 consecutive calendar d

Filing Documents

• enzn-20231231x10k.htm (10-K) — 774KB
• enzn-20231231xex4d1.htm (EX-4.1) — 40KB
• enzn-20231231xex21d1.htm (EX-21.1) — 4KB
• enzn-20231231xex23d1.htm (EX-23.1) — 4KB
• enzn-20231231xex31d1.htm (EX-31.1) — 15KB
• enzn-20231231xex32d1.htm (EX-32.1) — 6KB
• 0001410578-24-000245.txt (&nbsp;) — 3709KB
• enzn-20231231.xsd (EX-101.SCH) — 34KB
• enzn-20231231_cal.xml (EX-101.CAL) — 29KB
• enzn-20231231_def.xml (EX-101.DEF) — 122KB
• enzn-20231231_lab.xml (EX-101.LAB) — 260KB
• enzn-20231231_pre.xml (EX-101.PRE) — 209KB
• enzn-20231231x10k_htm.xml (XML) — 378KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 5 Item 1B. Unresolved Staff Comments 9 Item 1C Cybersecurity 9 Item 2.

Properties

Properties 10 Item 3.

Legal Proceedings

Legal Proceedings 10 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 11 Item 6. Reserved 11 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 11 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 17 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 17 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 17 Item 9A.

Controls and Procedures

Controls and Procedures 17 Item 9B. Other Information 19 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection 19 PART III Item 10. Directors, Executive Officers and Corporate Governance 19 Item 11.

Executive Compensation

Executive Compensation 19 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 19 Item 13. Certain Relationships and Related Transactions, and Director Independence 19 Item 14. Principal Accounting Fees and Services 20 PART IV Item 15. Exhibits, Financial Statement Schedules 20 Item 16. Form 10-K Summary 21 2 Table of Contents Unless the context requires otherwise, references in this Annual Report on Form 10-K to "Enzon," the "Company," "we," "us," or "our" and similar terms mean Enzon Pharmaceuticals, Inc. and its subsidiaries. This Annual Report on Form 10-K contains forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this Annual Report on Form 10-K, other than statements that are purely historical, are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "could," "potential," "anticipates," "estimates," "plans," "would," or "intends" or the negative thereof, or other variations thereof, or comparable terminology, or by discussions of strategy. Forward-looking statements are based upon management's present expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements, including the risks and uncertainties set forth in Item 1A. Risk Factors of this Annual Report on Form 10-K. These risks and uncertainties should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. We cannot assure that the future results covered by the forward-looking statements will be achieved. All information in this Annual Report on Form 10-K speaks only

Business

Item 1. Business OVERVIEW Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the "Company," "Enzon," "we" or "us") is positioned as a public company acquisition vehicle, where we can become an acquisition platform and potentially utilize our net operating loss carryforwards ("NOLs") in an effort to enhance stockholder value. In September 2020, we initiated a rights offering (the "Rights Offering") for our common and preferred stock, which closed in October 2020 (see below and Note 12 to our Consolidated Financial Statements), and we realized $43.6 million in gross proceeds. This has enabled us to embark on our plan to potentially realize the value of our approximately $102.5 million NOLs by acquiring businesses or assets, although there can be no assurance that we will be able to realize all or any portion of such value. To protect the NOLs, in August 2020, our Board of Directors (the "Board") adopted a Section 382 rights plan (see Note 11 to our Consolidated Financial Statements). Historically, we have received royalty revenues from licensing arrangements with other companies primarily related to sales of certain drug products that utilized Enzon's proprietary technology. In recent years, we have had no clinical operations and limited corporate operations. We have a marketing agreement relating to the drug Vicineum, which, if approved, will potentially generate milestone and royalty payments to us in the future. Currently, our licensee for this drug has announced that it is seeking a partner for further development of Vicineum. Accordingly, we cannot assure you that we will earn material future royalties or milestones from Vicineum or any other licensed patent. Acquisition Activities Our Board and our management are actively involved in pursuing, sourcing, reviewing, and evaluating various potential acquisition transactions consistent with our strategy. Our management and our Board have originated a number of potential acquisition opportunities a

Risk Factors

Item 1A. Risk Factors You should carefully consider the following risk factors, as well as other information in this Annual Report, including our financial statements and the related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations", as well as our other public filings. Our business, financial condition and results of operations may be impacted by one or more of the following factors, any of which could cause actual results to vary materially from historical and current results or anticipated future results. Risks Relating to the Company and its Operations Our search for a business, company or assets to acquire or in which to invest may be unsuccessful, or it could result in a change of control, and we may fail to utilize the proceeds of our Rights Offering and/or realize the value of our NOLs. We are positioned as a public company acquisition vehicle, where we can become an acquisition platform and potentially utilize our NOLs and enhance stockholder value. Although we may acquire businesses, entities or revenue streams that could generate sufficient income so that we can utilize our approximately $102.5 million in federal NOLs, there can be no assurance we will be able to do so. In addition, we do not have any current plans, arrangements or understandings with respect to any acquisitions or investments, and we may pursue acquisitions that could result in a change of control of us. Although we have had significant discretion in the use of the net proceeds of our Rights Offering, it is possible that we may not utilize such proceeds and if a transaction is pursued that results in a change of control, as defined in the Certificate of Designation of the Series C Non-Convertible Preferred Stock, holders of the Series C Non-Convertible Redeemable Preferred Stock will be entitled to redemption rights, and if exercised would require the Company to redeem such preferred stock. Further, if such change of control occurs,

View Full Filing

View this 10-K filing on SEC EDGAR